Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2785 - Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) in Patients with Pulmonary Carcinoid Tumours: Prevalence and Prognosis of an Under-Recognised Disease

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Aimee Hayes

Citation

Annals of Oncology (2018) 29 (suppl_8): viii467-viii478. 10.1093/annonc/mdy293

Authors

A.R. Hayes1, J. Banks2, H. Shah2, T.V. Luong1, S. Navalkissoor1, A. Grossman1, D. Mandair1, C. Toumpanakis1, M. Caplin1

Author affiliations

  • 1 Neuroendocrine Tumour Unit, Royal Free Hospital, NW3 2QG - London/GB
  • 2 Medical School, University College of London, London/GB
More

Resources

Abstract 2785

Background

DIPNECH is considered a rare condition and the natural history is poorly described. Its prevalence is likely underestimated given the absence of routine reporting on histopathology and often insufficient background lung parenchyma in the setting of lung biopsy. It is thought to give rise to pulmonary carcinoids (PCs) (>5 mm) or tumourlets (≤5 mm). We aimed to assess the prevalence and characteristics of DIPNECH in the PC population and to investigate predictors of progression-free (PFS) and overall survival (OS).

Methods

We identified patients with PCs plus histologically-proven DIPNECH and/or high suspicion of DIPNECH on imaging. The relationship between baseline characteristics and PFS and OS was analysed using the Kaplan-Meier method and curves were compared using the logrank test.

Results

46/233 (20%) patients with well-differentiated PCs and DIPNECH were identified (91% female, 52% never smokers, 50% cough and/or dyspnoea at time of diagnosis, 76% typical carcinoids (TC), 24% atypical carcinoids (AC), 9% both TC and AC) had median follow-up 37 mo (range 2-138 mo). Multicentric carcinoids were demonstrated in 11 (24%) patients on histopathology and a further 26 (57%) patients had synchronous carcinoids suggested on enhanced CT (multiple nodules >5 mm). Median PFS was 10.4 years. Six (13%) patients developed regional or distant metastases after a median of 25 months (8-125 mo) and most patients had higher proliferative indices on biopsy of metastases compared to histopathology at diagnosis. Atypical carcinoid morphology (PFS p-value 0.0006, OS p-value 0.03) and carcinoid TNM stage (PFS p-value p < 0.0001, OS p-value 0.006) was associated with shorter PFS and poorer OS. Of the entire cohort, ten year survival rate was 87%. Median OS was not reached.

Conclusions

DIPNECH may be more prevalent in the PC population than previously appreciated, especially in women. Whilst our results confirm DIPNECH is predominantly an indolent disease associated with TCs, up to one quarter of patients may develop ACs and these patients may warrant closer observation. Median PFS is long and lifelong follow-up is recommended.

Clinical trial identification

Legal entity responsible for the study

Aimee Hayes.

Funding

Has not received any funding.

Editorial Acknowledgement

Not applicable

Disclosure

A. Grossman: Lecture fees: Novartis, Ipsen, HRA Pharma, Pfizer, but none for the past 12 months. C. Toumpanakis: Speaker honoraria: Ipsen, Novartis, AAA. M. Caplin: Advisory board and speaker honoraria: Novartis, Ipsen, AAA, Lexicon. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings